ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est
Benzinga Newsdesk 1 day ago
NewsGuidance
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 analyst estimate. Narrows FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.085 billion-$1.125
ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 analyst estimate. Narrows FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.085 billion-$1.125 billion vs $1.102 billion estimate.